The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
zanolimumab
A human IgG1k monoclonal antibody against the CD4 receptor on T lymphocytes, with potential antineoplastic and immunosuppressing activities. Zanolimumab targets and binds to the CD4 receptor on certain T cells thereby preventing the interaction between the CD4 receptor and the major histocompatibility complex class II molecule. This prevents activation of CD4-positive T cells. In addition, zanolimumab is able to induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD4-expressing tumor cells. CD4, a receptor located on a subset of T-lymphocytes, is upregulated in T-cell lymphomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | anti-CD4 monoclonal antibody HuMax HuMax-CD4 monoclonal antibody MOAB HuMax-CD4 monoclonal antibody HuMax-CD4 | |
| |||
| Code names: | | HuMax-CD4 MDX-016 | |
| |||
